{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunity+Disorders&page=114",
    "query": {
      "condition": "Immunity Disorders",
      "page": 114
    },
    "page_size": 10
  },
  "pagination": {
    "page": 114,
    "page_size": 10,
    "total_count": 21235,
    "total_pages": 2124,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunity+Disorders&page=115&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunity+Disorders&page=113&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-10T11:00:16.217Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07735637",
      "title": "A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Newly Diagnosed Multiple Myeloma (NDMM)"
      ],
      "interventions": [
        {
          "name": "AZD0120",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Melphalan (part of ASCT)",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 750,
      "start_date": "2026-09-24",
      "completion_date": "2039-11-17",
      "has_results": false,
      "last_update_posted_date": "2026-10-21",
      "last_synced_at": "2026-11-10T11:00:16.217Z",
      "location_count": 46,
      "location_summary": "Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 37 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07735637"
    },
    {
      "nct_id": "NCT03154541",
      "title": "SynRinse Irrigation Pilot (SIP) Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Sinusitis, Chronic",
        "Cystic Fibrosis With Other Manifestations"
      ],
      "interventions": [
        {
          "name": "Synrinse",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2017-06-06",
      "completion_date": "2018-05-30",
      "has_results": false,
      "last_update_posted_date": "2018-10-17",
      "last_synced_at": "2026-11-10T11:00:16.217Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03154541"
    },
    {
      "nct_id": "NCT01828294",
      "title": "Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myasthenia Gravis"
      ],
      "interventions": [
        {
          "name": "Subcutaneous immunoglobulins",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Louis University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 4,
      "start_date": "2011-10",
      "completion_date": "2017-12",
      "has_results": false,
      "last_update_posted_date": "2019-04-03",
      "last_synced_at": "2026-11-10T11:00:16.217Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • St Louis, Missouri",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01828294"
    },
    {
      "nct_id": "NCT00082394",
      "title": "A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus I",
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "Trizivir",
          "type": "DRUG"
        },
        {
          "name": "atazanavir",
          "type": "DRUG"
        },
        {
          "name": "Combivir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2004-04-26",
      "completion_date": "2006-03-01",
      "has_results": false,
      "last_update_posted_date": "2017-05-24",
      "last_synced_at": "2026-11-10T11:00:16.217Z",
      "location_count": 43,
      "location_summary": "Bakersfield, California • Los Angeles, California • Oakland, California + 35 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00082394"
    },
    {
      "nct_id": "NCT01212094",
      "title": "Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "normal saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 44,
      "start_date": "2010-09",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2016-03-28",
      "last_synced_at": "2026-11-10T11:00:16.217Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01212094"
    },
    {
      "nct_id": "NCT02418494",
      "title": "Health-Related Symptom Questionnaires in Measuring Quality of Life in HIV-Infected Participants Treated or Monitored for Anal Lesions",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "High Grade Anal Canal Squamous Intraepithelial Neoplasia",
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "Concept Elicitation",
          "type": "OTHER"
        },
        {
          "name": "Comprehension Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "AIDS Malignancy Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "35 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2015-04",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2016-06-09",
      "last_synced_at": "2026-11-10T11:00:16.217Z",
      "location_count": 6,
      "location_summary": "San Francisco, California • Chicago, Illinois • New York, New York + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02418494"
    },
    {
      "nct_id": "NCT05947851",
      "title": "A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Leukemia, Lymphocytic, Chronic, B-Cell",
        "Leukemia, Chronic Lymphocytic",
        "Small-Cell Lymphoma",
        "Lymphoma, Small Lymphocytic",
        "CLL",
        "SLL"
      ],
      "interventions": [
        {
          "name": "Nemtabrutinib",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 735,
      "start_date": "2023-08-08",
      "completion_date": "2035-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-11-06",
      "last_synced_at": "2026-11-10T11:00:16.217Z",
      "location_count": 25,
      "location_summary": "Springdale, Arkansas • Long Beach, California • Clermont, Florida + 22 more",
      "locations": [
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Clermont",
          "state": "Florida"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05947851"
    },
    {
      "nct_id": "NCT00002431",
      "title": "The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Candidiasis, Oral",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Chlorhexidine gluconate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Procter and Gamble",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "13 Years to 75 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-11-10T11:00:16.217Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • San Francisco, California • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002431"
    },
    {
      "nct_id": "NCT05723653",
      "title": "Hybrid Type I Effectiveness-Implementation Trial of a Social Network Support Intervention",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Seropositivity"
      ],
      "interventions": [
        {
          "name": "Social Network Support Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 900,
      "start_date": "2023-02-13",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-11-10T11:00:16.217Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Chicago, Illinois + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05723653"
    },
    {
      "nct_id": "NCT01347437",
      "title": "Improving Antiretroviral Medication Adherence Among HIV-infected Youth",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "Positive STEPS",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Fenway Community Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "24 Years",
        "sex": "ALL",
        "summary": "13 Years to 24 Years"
      },
      "enrollment_count": 17,
      "start_date": "2011-07",
      "completion_date": "2013-03-06",
      "has_results": false,
      "last_update_posted_date": "2017-04-17",
      "last_synced_at": "2026-11-10T11:00:16.217Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01347437"
    }
  ]
}